NumFin

Arrowhead Pharmaceuticals, Inc.

Sümbol: ARWR

NASDAQ

24.44

USD

Turuhind täna

  • -8.8447

    P/E suhe

  • 0.1429

    PEG suhe

  • 3.03B

    MRK Cap

  • 0.00%

    DIV tootlus

Arrowhead Pharmaceuticals, Inc. (ARWR) Finantsaruanded

Download
AastaneQuarterly
LineaarneLog
Diagrammil näete Arrowhead Pharmaceuticals, Inc. (ARWR) vaikimisi numbreid dünaamikates. Companys revenue näitab keskmist 34.687 M, mis on 7.711 % gowth. Kogu perioodi keskmine brutokasum on 33.808 M, mis on 7.752 %. Keskmine brutokasumi suhtarv on 0.866 %. Ettevõtte eelmise aasta tulemuse puhaskasv on 0.163 %, mis on võrdne -0.900 % % keskmiselt kogu ettevõtte ajaloo jooksul.,

AastaneQuarterly
10Y20Y30Y40Y

Bilanss

Sukeldudes Arrowhead Pharmaceuticals, Inc. fiskaalkäiguteele, täheldame keskmist varade kasvu. See määr on huvitaval kombel , mis kajastab nii ettevõtte kõrg- kui ka madalseisusid. Kui võrrelda kvartalite lõikes, siis kohandub see näitaja 0. Kui vaadata tagasi möödunud aastale, siis on varade kogumuutus 0.106. Käibevara valdkonnas on ARWR aruandlusvaluutas 110.891. Märkimisväärne osa neist varadest, täpsemalt 110.891, hoitakse sularahas ja lühiajalistes investeeringutes. See segment näitab eelmise aasta andmetega võrreldes muutust -0.705%. Ettevõtte pikaajalised investeeringud, kuigi need ei ole tema fookuses, seisavad 292.735, kui neid on, aruandlusvaluutas. See näitab erinevust 176.499% võrreldes eelmise aruandeperioodiga, mis kajastab ettevõtte strateegilisi muutusi. Ettevõtte võlaprofiil näitab, et ettevõtte pikaajaline koguvõlg on 104.608 aruandlusvaluutas. See näitaja tähendab, et aastane muutus on 0.412%. Aktsionäride väärtus, mida näitab aktsionäride kogu omakapital, on hinnatud 271.343 aruandlusvaluutas. Selle aspekti aastane muutus on 1.561%. Kui süveneda ettevõtte finantsnäitajatesse, ilmneb täiendavaid üksikasju. Netovõlad on hinnatud 0, varude hind on 0 ja firmaväärtus 0, kui see on olemas. Kogu immateriaalne vara, kui see on olemas, hinnatakse 10.26.

common:word.in-mln

USD
Growth
TTM202320222021202020192018201720162015201420132012201120102009200820072006200520042003200220012000199919981997

balance-sheet.row.cash-and-short-term-investments

1556.61110.9376.4367.8
315.5
258.7
76.5
65.6
85.4
98.8
154.2
28.1
3.5
8.1
6.8
2
10.1
24.1
28
22.5
9
1.4
0
0
0
0
0
0

balance-sheet.row.short-term-investments

1147.21292.7268.4183.4
171.9
36.9
46.4
40.8
0
17.5
21.7
9
0.1
0.6
0
0
0
0
0
0.1
0.5
0
0
0
0
0
0
0

balance-sheet.row.net-receivables

70.6801.410.3
0.8
0.7
0.3
0.1
0.1
0
0
0.1
2.5
1.6
0.9
0.1
0.1
0.3
0.1
0
0.1
0
0
0
0
0
0
0

balance-sheet.row.inventory

19.990-21.64.4
4.3
3.3
1.3
0.9
1.3
0
0
0
0
0
0.2
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-current-assets

35.787.120.22.2
1.8
2.6
0.6
1.4
3.8
0.8
0
0.6
0.6
0.1
0.1
0.3
0.4
0.9
0.7
0.2
0.4
0.2
0
0
0
0
0
0

balance-sheet.row.total-current-assets

1702.39110.9376.4384.6
322.4
265.2
78.8
67.9
90.5
102.9
154.8
28.8
6.6
9.9
8.1
2.5
10.6
25.3
28.8
22.8
9.5
1.5
0
0
0
0
0
0

balance-sheet.row.property-plant-equipment-net

1212.26335.6168.666
47
23.2
13.9
15.5
15.4
4.5
3.9
3.5
4.9
0
0.1
0.5
1.2
1.4
1.3
1.1
0.9
0
0
0
0
0.1
0
0.1

balance-sheet.row.goodwill

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1.8
0.4
0
0
0
0
0
0
0

balance-sheet.row.intangible-assets

41.910.31213.7
15.4
17.1
18.8
20.5
22.2
24.8
1
3.2
4.8
1.7
2
2.4
2.7
2.9
3.4
5
1.5
0
0
0
0
0
0
0

balance-sheet.row.goodwill-and-intangible-assets

41.910.31213.7
15.4
17.1
18.8
20.5
22.2
24.8
1
3.2
4.8
1.7
2
2.4
2.7
2.9
4.3
5
1.5
0
0
0
0
0
0
0

balance-sheet.row.long-term-investments

121.59292.7105.9245.6
137.5
44.2
0
0
0
0
23.1
0
0
1.8
2
2.2
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.tax-assets

0-345.800
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-non-current-assets

0.86361.929.10.3
0.3
0.1
0.1
0.1
0.1
0
0
1.7
0.3
2.4
0
0.1
2.7
0.2
0.2
0.1
0.1
0
0
0
0
0
0
0

balance-sheet.row.total-non-current-assets

1376.61654.7315.5325.6
200.1
84.6
32.8
36.1
37.7
29.4
28
8.5
10
6
4.2
5.2
6.7
4.5
5.8
6.2
2.4
0
0
0
0
0.1
0.1
0.1

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-assets

3079765.6691.9710.1
522.5
349.8
111.6
104
128.2
132.3
182.8
37.3
16.5
15.9
12.4
7.7
17.3
29.9
34.5
29
11.9
1.5
0.1
0
0.1
0.1
0.1
0.1

balance-sheet.row.account-payables

57.7635.92.99.5
6.8
7.6
2.8
4.1
12.2
5
2.6
1.2
0.9
0.6
0.7
1
1.3
1.3
0.8
0.5
0.5
0.1
0.3
0.2
0.2
0.2
1.1
1.4

balance-sheet.row.short-term-debt

19.5210.62.82.3
1.1
11.6
0.2
0.2
0.2
0.2
0.3
1.2
0.2
0
0.5
0.7
0.8
1
0
0
0
0
0.6
0.5
0.5
0.5
1
1

balance-sheet.row.tax-payables

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.long-term-debt-total

379.75104.678.823.3
20
0
2.1
2.3
2.5
0.5
0.8
1.1
2.1
0.6
0
0.5
0.7
0
0
0
0
0
0
0
0
0
0.3
0

Deferred Revenue Non Current

1.07056131.5
0
5
0
0
2.5
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

146.29-46.4-5.623.8
13.5
0
9.3
9.1
10.6
10.5
8.9
6.2
4.2
2
2.4
0.2
0.5
0.4
2.1
0.4
0.1
0
0.7
0
0.5
0.3
0.3
0.2

balance-sheet.row.total-non-current-liabilities

1444.48477.5511.9154.8
20
8.7
4
4.5
7.5
6.7
5
2.9
2.4
0.7
0
0.5
1.2
0.5
934.4
1.9
1.8
0
0
0
0
0
0
0

balance-sheet.row.other-liabilities

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-934.4
-1.9
-1.8
0
0
0
0
0
0
0

balance-sheet.row.capital-lease-obligations

399.26115.281.625.5
21.1
0
0
0
0
0.8
1
1.3
1.5
0
0
0.7
0.7
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-liab

1771.04478.4586301.3
60.7
105.8
16.4
23.2
33.2
22.6
16.8
11.6
7.7
3.3
4.3
2.8
5
3.4
2.9
1
0.7
0.1
1.6
1.4
1.2
1.1
2.7
2.7

balance-sheet.row.preferred-stock

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1162
0
0
0
0
0
0
0
0
0

balance-sheet.row.common-stock

0.80.21060.2
0.2
0.2
0.2
0.2
0.2
0.2
0.1
0.1
0.1
0.1
0.1
0.1
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.retained-earnings

-3914.68-1026-820.8-644.7
-503.8
-419.3
-487.3
-432.8
-398.4
-316.7
-224.8
-166.1
-135
-113.9
-110.7
-105
-85.5
-58.4
-28.5
-9.2
-2.6
-0.1
-9.6
-9.4
-9.2
-9
-9.5
-9.4

balance-sheet.row.accumulated-other-comprehensive-income-loss

-5.22-3.2-0.1-0.1
0
-0.4
0
0
0
-0.1
-4.2
-3.1
-1.6
-0.3
-1.2
-1
-1.6
-1.7
-1.1
-0.7
-0.2
0
-0.1
0
-0.1
-0.1
-0.1
-0.1

balance-sheet.row.other-total-stockholders-equity

5162.451300.4820.91053.4
965.4
664.1
582.9
514
493.8
426.9
395.4
196.6
146.5
126.9
120.9
110.8
99.4
86.3
-1101.8
36
12.2
1.5
8.1
8.1
8.1
8.1
6.9
6.9

balance-sheet.row.total-stockholders-equity

1243.35271.3106408.8
461.8
244.6
95.8
81.4
95.6
110.2
166.5
27.5
10
12.8
9
4.9
12.3
26.3
30.7
26.1
9.4
1.4
-1.6
-1.3
-1.1
-1
-2.6
-2.6

balance-sheet.row.total-liabilities-and-stockholders-equity

3079765.6691.9710.1
522.5
349.8
111.6
104
128.2
132.3
182.8
37.3
16.5
15.9
12.4
7.7
17.3
29.9
34.5
29
11.9
1.5
0.1
0
0.1
0.1
0.1
0.1

balance-sheet.row.minority-interest

64.6115.819.80
0
-0.6
-0.6
-0.6
-0.6
-0.6
-0.6
-1.8
-1.2
-0.2
-1
0
0
0.2
0.9
1.9
1.8
0
0
0
0
0
0
0

balance-sheet.row.total-equity

1307.97287.2125.8408.8
461.8
244
95.2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.total-liabilities-and-total-equity

3079---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

Total Investments

1268.81292.7374.3428.9
309.4
81.1
46.4
40.8
0
17.5
44.7
9
0.1
2.5
2
2.2
0
0
0
0.1
0.5
0
0
0
0
0
0
0

balance-sheet.row.total-debt

399.26115.281.625.5
21.1
0
2.3
2.5
2.7
0.8
1
2.3
2.3
0.6
0.5
1.2
1.5
0
1.2
0
0
0
0.6
0.6
0.6
0.6
1.3
1

balance-sheet.row.net-debt

-10.134.3-26.4-158.9
-122.4
-221.8
-27.8
-22.3
-82.6
-80.5
-131.5
-16.8
-1
-6.9
-6.3
-0.8
-8.6
-24.1
-26.8
-22.5
-8.6
-1.4
0.6
0.6
0.6
0.6
1.3
1

Rahavoogude aruanne

Arrowhead Pharmaceuticals, Inc. finantsmaastikul on viimase perioodi jooksul toimunud märkimisväärne muutus vabas rahavoos, mis näitab -0.750 nihet. Ettevõte laiendas hiljuti oma aktsiakapitali, emiteerides 3.05, mis tähistab -99.811 erinevust võrreldes eelmise aastaga. Huvitav on see, et osa ettevõtte aktsiatest, täpsemalt 0, ostis ettevõte ise tagasi. Selle tegevuse tulemusena muutus 0.000 võrreldes eelmise aastaga. Vahepeal on ettevõtte võlgnevused praegu 33 aruandlusvaluutas. Ettevõtte investeerimistegevuse tulemusel kasutas ettevõte netosularaha, mis aruandlusvaluutas oli -96155000.000. See on 16.751 nihkumine võrreldes eelmise aastaga. Samal perioodil registreeris ettevõte 12.49, 80.58, -250, mis on olulised ettevõtte investeerimis-ja tagasimaksestrateegiate mõistmiseks. Ettevõtte finantseerimistegevuse tulemusel kasutas ettevõte netorahavahendeid 0.000, kusjuures erinevus võrreldes eelmise aastaga oli 0.000. Lisaks eraldas ettevõte 0 aktsionäridele dividendide maksmiseks. Samal ajal tegi ta muid finantsmanöövreid, millele viidatakse kui 500, mis samuti mõjutasid oluliselt tema rahavooge sel perioodil. Need komponendid koos annavad tervikliku pildi ettevõtte finantsseisundist ja strateegilisest lähenemisest rahavoogude juhtimisele.

common:word.in-mln

USD
Growth
TTM202320222021202020192018201720162015201420132012201120102009200820072006200520042003200220012000199919981997

cash-flows.row.net-income

-302.84-209.3-176.5-140.8
-84.6
68
-54.5
-34.4
-81.7
-91.9
-58.6
-31.1
0
-8.8
-6.2
-19.3
-27.1
-29.9
-19
-6.6
-2.5
-0.1
-0.2
-0.2
-0.1
0.6
-0.1
-0.9

cash-flows.row.depreciation-and-amortization

14.0712.510.48.3
5.9
4.4
4.7
4.7
3.3
2.3
1.3
1.8
1.7
0.3
0.7
1
1.1
1
0.9
0.6
0.1
0
0
0
0
0
0
0.1

cash-flows.row.deferred-income-tax

-2.93-34.400
0
0
-0.4
-0.9
2.4
-2.9
8.1
7.7
-0.6
1.5
0
-1.3
0
0
-1371.1
0
-0.1
0
0
0
0
0
0
0

cash-flows.row.stock-based-compensation

78.4378.1120.976.7
43.4
12.4
8.5
7.9
11.6
10.2
5.7
1.5
1.2
1.4
1.6
2.7
0
0
1369.5
0
0.1
0
0
0
0
0
0
0

cash-flows.row.change-in-working-capital

-3.1-51.5-98.3226.9
-60.7
87.2
-5.9
-1.2
5.7
3.4
5
0.1
0.2
0
-1
-0.8
-0.2
0
1.4
0.4
0
-0.1
0.2
0.2
0
0.1
0
0.1

cash-flows.row.account-receivables

39.571.48.8-9.4
-0.2
-0.3
-0.3
0
-0.1
0
0.1
-0.1
162.9
0
0
-60.7
0
0
-40.8
0
-0.1
0
0
0
0
0
0
0

cash-flows.row.inventory

2.4-3.409.2
1.6
-1.3
1.3
2.4
-1.9
0
-139.4
-20.2
-162.9
0
0
60
0
0
-328.3
0
-9
0
0
0
0
0
0
0

cash-flows.row.account-payables

22.6133-6.62.6
-0.8
4.8
-1.3
-3.5
2.6
2.5
1.4
0.3
0.3
0.2
-0.3
-0.3
0
0
370.4
0
0.2
0
0
0
0
0
0
0

cash-flows.row.other-working-capital

-67.67-82.6-100.5224.5
-61.3
83.9
-5.7
-0.1
5.1
0.9
143
20.1
0
-0.2
-0.7
0.1
-0.2
0
0.1
0.4
8.8
-0.1
0.2
0.1
0
0.1
0
0.1

cash-flows.row.other-non-cash-items

20.1550.77.30.3
0.5
1.1
0.4
0
-5.6
13.1
3.1
1
-18
0.2
-2.7
2.5
-1.4
5
3.6
-3.6
0.1
0
-0.1
-0.1
0
-0.7
0
0.7

cash-flows.row.net-cash-provided-by-operating-activities

-196.21000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

-206.48-176.7-52.8-23.6
-12
-12
-1.4
-7.9
-3.9
-2
-1.7
-0.3
-0.5
0
0
0
-0.7
-0.8
-0.9
-0.7
-0.7
0
0
0
0
0
0
0

cash-flows.row.acquisitions-net

-122.36-80.6-47.4141.7
240777.8
47746
7435
0
0
-10
0
0
0.1
-1.7
0
0
0.1
5.1
205.1
-8
0.3
0
0
0
0
0
0
0

cash-flows.row.purchases-of-investments

-134.94-246.1-223.4-240.7
-279
-90.3
-52.1
-45
0
0
-46.4
-10.7
0
1700.4
0
0
0
0
-18.6
2.4
0
0
0
0
0
0
0
0

cash-flows.row.sales-maturities-of-investments

390.8326.7270.8122.6
50.1
54.5
46.1
4.2
17.3
26.1
11.6
1.4
0.5
1.5
0
0.7
0
0
19
0.5
0
0
0
0
0
0
0
0

cash-flows.row.other-investing-activites

255.8680.647.4-141.7
-240777.8
-47746
-7435
0
0
0
0
0.1
0.3
-1700.4
0.5
0.1
-2
0
-205.1
8
0
0
0
0
0
0
0
0

cash-flows.row.net-cash-used-for-investing-activites

49.38-96.2-5.4-141.7
-240.8
-47.7
-7.4
-48.6
13.4
14.1
-36.5
-9.5
0.4
-0.2
0.5
0.7
-2.6
4.4
-0.5
2.3
-0.4
0
0
0
0
0
0
0

cash-flows.row.debt-repayment

-250-25000
0
-2.4
-0.2
-0.2
-0.2
-0.2
-0.2
-0.2
-0.2
0
-0.7
-0.8
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.common-stock-issued

1.353.15.211.3
250.5
60.5
56.6
12.4
52.2
0
172.6
44.5
11
6.2
12.2
4.8
16.3
15.6
20.9
20.7
9.9
0
0
0
0
0
0
0

cash-flows.row.common-stock-repurchased

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.dividends-paid

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-financing-activites

252.185006011.3
7.5
8.3
3.6
-0.2
3.1
0.5
12.9
0
0
0
0.6
2.5
-0.1
0
0
0
0
1.5
0.1
0.1
0.1
0
0
0

cash-flows.row.net-cash-used-provided-by-financing-activities

2.74253.165.211.3
257.9
66.4
60
12.1
55.1
0.3
185.3
44.3
10.8
6.2
12
6.5
16.1
15.6
20.9
20.7
9.9
1.5
0.1
0.1
0.1
0
0
0

cash-flows.row.effect-of-forex-changes-on-cash

0.06-0.1-0.1-0.1
0.4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-1.4
0
0
0
0
0
0
0

cash-flows.row.net-change-in-cash

-144.032.9-76.440.9
-78.2
191.7
5.3
-60.5
4.2
-51.3
113.4
15.7
-4.1
0.7
4.8
-8.1
-14
-3.9
5.6
13.9
5.8
1.4
0
0
0
0
0
0

cash-flows.row.cash-at-end-of-period

409.4110.9108184.4
143.6
221.8
30.1
24.8
85.4
81.2
132.5
19.1
3.4
7.5
6.8
2
10.1
24.1
28
22.5
7.2
1.4
0
0
0
0
0
0

cash-flows.row.cash-at-beginning-of-period

553.43108184.4143.6
221.8
30.1
24.8
85.4
81.2
132.5
19.1
3.4
7.5
6.8
2
10.1
24.1
28
22.5
8.6
1.4
0
0
0
0
0
0
0

cash-flows.row.operating-cash-flow

-196.21-153.9-136.1171.2
-95.4
173
-47.2
-23.9
-64.4
-65.7
-35.4
-19
-15.3
-5.4
-7.7
-15.3
-27.6
-23.9
-14.8
-9.1
-2.3
-0.2
-0.1
-0.1
-0.1
0
0
0

cash-flows.row.capital-expenditure

-206.48-176.7-52.8-23.6
-12
-12
-1.4
-7.9
-3.9
-2
-1.7
-0.3
-0.5
0
0
0
-0.7
-0.8
-0.9
-0.7
-0.7
0
0
0
0
0
0
0

cash-flows.row.free-cash-flow

-402.7-330.6-188.9147.7
-107.3
161
-48.6
-31.9
-68.3
-67.7
-37.1
-19.3
-15.8
-5.4
-7.7
-15.3
-28.3
-24.6
-15.7
-9.8
-3
-0.2
-0.1
-0.1
-0.1
0
0
0

Kasumiaruande rida

Arrowhead Pharmaceuticals, Inc. tulud muutusid võrreldes eelmise perioodiga -0.010%. ARWR brutokasum on teatatud 228.24. Ettevõtte tegevuskulud on 445.74, mille muutus võrreldes eelmise aastaga on 5.690%. Kulud amortisatsioonikulud on 12.49, mis on 0.199% muutus võrreldes eelmise aruandeperioodiga. Tegevuskulud on teatatud 445.74, mis näitab 5.690% muutust võrreldes eelmise aastaga. Müügi- ja turunduskulud on 0, mis on 0.000% muutus võrreldes eelmise aastaga. Hiljutistel numbritel põhinev EBITDA on 0, mis tähendab -0.148% kasvu võrreldes eelmise aastaga. Tegevustulu on -205, mis näitab 0.148% muutust võrreldes eelmise aastaga. Puhaskasumi muutus on 0.163%. Eelmise aasta puhaskasum oli -205.28.

common:word.in-mln

USD
Growth
TTM202320222021202020192018201720162015201420132012201120102009200820072006200520042003200220012000199919981997

income-statement-row.row.total-revenue

181.74240.7243.2138.3
88
168.8
16.1
31.4
0.2
0.4
0.2
0.3
0.1
0.3
0.6
3.8
1.3
1.2
0.6
0.6
0.2
0
0
0
0
0
0.1
0.1

income-statement-row.row.cost-of-revenue

14.0712.510.40
0
0
0
0
0
0
0
0
0
0
0
0
0
0.7
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.gross-profit

167.67228.2232.8138.3
88
168.8
16.1
31.4
0.2
0.4
0.2
0.3
0.1
0.3
0.6
3.8
1.3
0.5
0.6
0.6
0.2
0
0
0
0
0
0
0

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

385.98---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

93.54---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

1.851.55.82.1
-0.6
0
0
1.3
0.1
0.4
0.1
-1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.operating-expenses

481.15445.7421.7287.3
181.2
107.6
72.1
68.4
79.9
96.4
51.3
23.6
21.2
10.1
9.4
23.5
36.3
38.4
21.8
10
3
0.1
1.4
0.1
0.1
0.1
0.1
0.2

income-statement-row.row.cost-and-expenses

481.15445.7421.7287.3
181.2
107.6
72.1
68.4
79.9
96.4
51.3
23.6
21.2
10.1
9.4
23.5
36.3
39.2
21.8
10
3
0.1
1.4
0.1
0.1
0.1
0.1
0.2

income-statement-row.row.interest-income

15.4215.356.1
9.2
7
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.interest-expense

20.8418.356.1
9190.5
6957.8
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

0.951.55.88.2
8.6
7
0.4
2.2
-2.3
3.3
-8.3
-8.3
-1.1
1
1.5
0.6
-0.1
0
-0.7
2.4
0
0
0.1
0.1
0.1
-0.2
0
-0.7

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

1.851.55.82.1
-0.6
0
0
1.3
0.1
0.4
0.1
-1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.total-operating-expenses

0.951.55.88.2
8.6
7
0.4
2.2
-2.3
3.3
-8.3
-8.3
-1.1
1
1.5
0.6
-0.1
0
-0.7
2.4
0
0
0.1
0.1
0.1
-0.2
0
-0.7

income-statement-row.row.interest-expense

20.8418.356.1
9190.5
6957.8
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.depreciation-and-amortization

18.6412.510.48.3
5.9
4.4
4.7
4.7
3.3
2.3
1.3
1.8
1.7
0.3
0.7
1
1.1
1
0.9
0.6
0.1
0
0
0
0
0
0
0.1

income-statement-row.row.ebitda-caps

-268.48---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

-299.41-205-178.5-149
-93.2
61.2
-55.9
-37
-81.7
-96
-53.3
-24.6
-21.1
-9.8
-8.8
-19.7
-35
-37.9
-21.2
-9.4
-2.8
-0.1
-1.4
-0.1
-0.1
-0.1
0
-0.2

income-statement-row.row.income-before-tax

-303.39-206.5-172.7-140.8
-84.6
68.1
-54.4
-34.4
-81.7
-91.9
-58.7
-31.7
-22.1
-8.8
-7.3
-19.2
-35.1
-37.9
-21.9
-7
-2.5
-0.1
-0.2
-0.2
-0.1
-0.4
0
-0.9

income-statement-row.row.income-tax-expense

-1.542.83.80
0
0.2
0
0
0
0
0
6.2
-0.2
-6.9
-3.2
0.1
-8
-8
-2.2
-2.7
0
0
-1.2
0.1
0
-0.6
0
0.7

income-statement-row.row.net-income

-296.81-205.3-176.5-140.8
-84.6
68
-54.5
-34.4
-81.7
-91.9
-58.6
-31.1
-21.1
-3.1
-5.8
-19.3
-27.1
-29.9
-19
-6.6
-2.5
-0.1
-0.2
-0.2
-0.1
0.6
-0.1
-0.9
Sarnased aktsiad
Sind võib huvitada ka:
SRNE
Sorrento Therapeutics, Inc..
0.015 USD
NASDAQ
MRVI
Maravai LifeSciences Holdings, Inc..
8.97 USD
NASDAQ
CMRA
Comera Life Sciences Holdings, Inc..
0.03 USD
NASDAQ
GUBRA.CO
Gubra A/S.
300 DKK
CPH
T5O.DE
CytoTools AG.
0.468 EUR
XETRA
HBC.OL
Hofseth BioCare ASA.
2.1 NOK
OSL
6826.HK
Shanghai Haohai Biological Technology Co., Ltd..
42.35 HKD
HKSE
PPBT
Purple Biotech Ltd..
0.67 USD
NASDAQ

Korduma kippuv küsimus

Mis on Arrowhead Pharmaceuticals, Inc. (ARWR) koguvara?

Arrowhead Pharmaceuticals, Inc. (ARWR) koguvara on 765552000.000.

Mis on ettevõtte aastane tulu?

Aastane tulu on 19648000.000.

Mis on ettevõtte kasumimarginaal?

Ettevõtte kasumimarginaal on 0.923.

Mis on ettevõtte vaba rahavoog?

Vaba rahavoog on -3.749.

Mis on ettevõtte puhaskasumimarginaal?

Puhaskasumimarginaal on -1.633.

Mis on ettevõtte kogutulu?

Kogutulu on -1.647.

Mis on Arrowhead Pharmaceuticals, Inc. (ARWR) puhaskasum (puhaskasum)?

Puhaskasum (netotulu) on -205275000.000.

Kui suur on ettevõtte koguvõlg?

Koguvõlg on 115171000.000.

Mis on tegevuskulude arv?

Tegevuskulud on 445737000.000.

Milline on ettevõtte rahaline näitaja?

Ettevõtte raha on 58215000.000.